肝细胞癌监测:当前最佳实践与未来方向
肝细胞癌(HCC)是全球癌症死亡第四大原因,美国癌症死亡增长最快。专家学会指南推荐高危个体每6个月监测一次,但监测有效性仍有争议。本文讨论当前最佳实践及证据,并介绍改进监测的举措与未来研究方向。
要点
- 专家学会指南推荐高危个体每6个月进行HCC监测。
- HCC总体预后差,仅早期诊断并接受潜在治愈性治疗(如手术切除和肝移植)的患者亚群预后较好。
- 监测有效性仍存争议,未来方向为根据个体HCC风险定制监测测试和间隔的精准监测。
核心结论
- HCC总体预后仍差,仅早期诊断并接受潜在治愈性治疗(如手术切除和肝移植)的患者亚群除外。
- 尽管有指南推荐,HCC监测的有效性仍是争论主题。
- 作者认为改进监测的努力将推动领域走向精准监测,即根据个体HCC风险定制监测测试和间隔。
研究设计与样本
- 本文为综述,讨论HCC监测的当前最佳实践、支持推荐证据、改进举措及未来研究方向。
主要发现
- HCC是全球癌症死亡第四大原因,也是美国癌症死亡增长最快的原因。
- 专家学会指南推荐高危个体每6个月进行HCC监测。
- HCC监测的有效性仍是争论主题。
关键数值与推荐
- 专家学会指南推荐高危个体每6个月进行HCC监测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular cancer (HCC) is the fourth leading cause of cancer-related deaths worldwide and the fastest growing cause of cancer deaths in the United States. The overall prognosis of HCC remains dismal, except for the subset of patients who are diagnosed at early stage and receive potentially curative therapies, such as surgical resection and liver transplantation. Given this, expert society guidelines recommend HCC surveillance every 6 months in at-risk individuals. Despite these recommendations, the effectiveness of HCC surveillance remains a subject of debate. We discuss current best practices for HCC surveillance and the evidence that support these recommendations. We also describe several initiatives that are underway to improve HCC surveillance and outline areas that may serve as high-yield targets for future research. Overall, we believe these efforts will help the field move toward precision surveillance, where surveillance tests and intervals are tailored to individual HCC risk. Doing so can maximize surveillance benefits, minimize surveillance harms, and optimize overall value for all patients.
引用
- Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology. 2019. PMID: 30986389. doi:10.1053/j.gastro.2019.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。